SBI Securities Co. Ltd. Acquires Shares of 4,930 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

SBI Securities Co. Ltd. purchased a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 4,930 shares of the biotechnology company’s stock, valued at approximately $36,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. XML Financial LLC increased its holdings in shares of Iovance Biotherapeutics by 7.4% during the 3rd quarter. XML Financial LLC now owns 14,500 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,000 shares during the last quarter. Saturna Capital Corp grew its stake in shares of Iovance Biotherapeutics by 7.0% during the third quarter. Saturna Capital Corp now owns 20,553 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 1,353 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Iovance Biotherapeutics by 10.1% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 21,318 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 1,950 shares in the last quarter. Assetmark Inc. grew its stake in shares of Iovance Biotherapeutics by 48.0% during the third quarter. Assetmark Inc. now owns 12,853 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 4,167 shares in the last quarter. Finally, Clear Harbor Asset Management LLC grew its stake in Iovance Biotherapeutics by 34.2% in the fourth quarter. Clear Harbor Asset Management LLC now owns 23,550 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $3.90 on Wednesday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -2.62 and a beta of 0.93. Iovance Biotherapeutics, Inc. has a fifty-two week low of $3.58 and a fifty-two week high of $15.90. The firm has a fifty day moving average price of $5.78 and a two-hundred day moving average price of $8.24.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). The business had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. As a group, sell-side analysts expect that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IOVA has been the subject of a number of research reports. The Goldman Sachs Group decreased their target price on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Truist Financial lowered their price objective on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Finally, Piper Sandler lowered their price target on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.25.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.